Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 5183646, 4 pages
https://doi.org/10.1155/2017/5183646
Case Report

Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom’s Macroglobulinemia

1Geisinger Commonwealth School of Medicine, 521 Pine Street, Scranton, PA 18510, USA
2Division of Hematology and Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
3Hematology & Oncology Associates of Northeastern Pennsylvania, 1100 Meade Street, Dunmore, PA 18512, USA

Correspondence should be addressed to C. Barsigian; moc.nsm@naigisc

Received 15 September 2016; Revised 20 December 2016; Accepted 9 January 2017; Published 12 February 2017

Academic Editor: Uma Dasgupta

Copyright © 2017 D. Kazmierski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Leleu, W. Xie, M. Bagshaw et al., “The role of serum immunoglobulin free light chain in response and progression in Waldenstrom macroglobulinemia,” Clinical Cancer Research, vol. 17, no. 9, pp. 3013–3018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. X. Leleu, A.-S. Moreau, E. Weller et al., “Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia,” Leukemia and Lymphoma, vol. 49, no. 6, pp. 1104–1107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Ebana, K. Nakamura, Y. Nozawa, R. Seki, and M. Mita, “Serum free light chain only myeloma with cytoplasmic IgM,” Case Reports in Hematology, vol. 2014, Article ID 676913, 5 pages, 2014. View at Publisher · View at Google Scholar
  4. S. P. Treon, L. Xu, G. Yang et al., “MYD88 L265P somatic mutation in Waldenström's macroglobulinemia,” New England Journal of Medicine, vol. 367, no. 9, pp. 826–833, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Xu, Z. R. Hunter, G. Yang et al., “MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction,” Blood, vol. 121, no. 11, pp. 2051–2058, 2013. View at Publisher · View at Google Scholar
  6. C. Jiménez, E. Sebastián, M. C. Chillón et al., “MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia,” Leukemia, vol. 27, no. 8, pp. 1722–1728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. P. Treon, C. K. Tripsas, K. Meid et al., “Ibrutinib in previously treated Waldenström's macroglobulinemia,” New England Journal of Medicine, vol. 372, no. 15, pp. 1430–1440, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. P. Treon, L. Xu, and Z. Hunter, “MYD88 mutations and response to ibrutinib in Waldenström's Macroglobulinemia,” New England Journal of Medicine, vol. 373, no. 6, pp. 584–586, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. P. Treon and Z. R. Hunter, “A new era for Waldenstrom macroglobulinemia: MYD88 L265P,” Blood, vol. 121, no. 22, pp. 4434–4436, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. A. Dimopoulos, M. A. Gertz, E. Kastritis et al., “Update on treatment recommendations from the fourth international workshop on Waldenstrom's macroglobulinemia,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 120–126, 2008. View at Publisher · View at Google Scholar
  11. S. P. Treon, L. Ioakimidis, J. D. Soumerai et al., “Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180,” Journal of Clinical Oncology, vol. 27, no. 23, pp. 3830–3835, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Dimopoulos, R. Garćia-Sanz, M. Gavriatopoulou et al., “Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN),” Blood, vol. 122, no. 19, pp. 3276–3282, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Moreau, H. Pylypenko, S. Grosicki et al., “Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study,” The Lancet Oncology, vol. 12, no. 5, pp. 431–440, 2011. View at Publisher · View at Google Scholar · View at Scopus